Palo Alto Investors LP Relmada Therapeutics, Inc. Transaction History
Palo Alto Investors LP
- $626 Million
- Q4 2024
A detailed history of Palo Alto Investors LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 495,146 shares of RLMD stock, worth $128,737. This represents 0.04% of its overall portfolio holdings.
Number of Shares
495,146
Previous 732,400
32.39%
Holding current value
$128,737
Previous $2.37 Million
89.17%
% of portfolio
0.04%
Previous 0.33%
Shares
3 transactions
Others Institutions Holding RLMD
# of Institutions
54Shares Held
8.29MCall Options Held
364KPut Options Held
46.5K-
Franklin Resources Inc San Mateo, CA1.3MShares$338,5590.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$326,7430.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$319,2610.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$149,0610.0% of portfolio
-
Geode Capital Management, LLC Boston, MA303KShares$78,7370.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $7.44M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...